Therapeutic potential of targeting LAG-3 in cancer
Journal for ImmunoTherapy of Cancer · 2025-07 · 13 (7) · e011652
DOI: 10.1136/jitc-2025-011652 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 08.07.2025. Verfasst von Diwakar Davar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA davard@upmc.edu. Hauptthemen laut MEDLINE: Neoplasms, Antigens, CD, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Gateway Foundation for Cancer Research, Clinical Center.
Abstract (Originalsprache)
Immune checkpoint inhibitors targeting negative regulatory checkpoints including programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 have produced significant improvements in progression-free survival (PFS) and overall survival in multiple solid tumors. Lymphocyte activation gene 3 (LAG-3) is an inhibitory receptor that is highly expressed by exhausted T cells. Dual blockade of LAG-3 and PD-1 with monoclonal antibodies relatlimab and nivolumab has improved PFS in advanced melanoma, leading to Food and Drug Administration approval for this indication. Concurrently, enthusiasm for targeting LAG-3 has been tempered by negative results in multiple indications, although novel approaches including LAG-3-directed bispecifics tebotelimab continue to demonstrate promise. In this review, we discuss the current understanding of LAG-3 in regulating antitumor immunity and the ongoing state of clinical development of LAG-3-directed agents in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA davard@upmc.edu.
- Harvard Medical School, Boston, Massachusetts, USA.
- Oncology Global Clinical Development, GSK, Baar, Switzerland.
Förderung
- NCI NIH HHS
- Gateway Foundation for Cancer Research
- Clinical Center
Zitieren
APA
Davar, D., Anderson, A. C., & Diaz-Padilla, I. (2025). Therapeutic potential of targeting LAG-3 in cancer. Journal for ImmunoTherapy of Cancer, 13(7), e011652. https://doi.org/10.1136/jitc-2025-011652
Vancouver
Davar D, Anderson AC, Diaz-Padilla I. Therapeutic potential of targeting LAG-3 in cancer. Journal for ImmunoTherapy of Cancer. 2025;13(7):e011652. doi:10.1136/jitc-2025-011652
BibTeX
@article{Davar2025,
author = {Davar, Diwakar and Anderson, Ana Carrizosa and Diaz-Padilla, Ivan},
title = {Therapeutic potential of targeting LAG-3 in cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {7},
pages = {e011652},
doi = {10.1136/jitc-2025-011652}
}
EUVIMED